The Cell Shuttle enables end-to-end automation of the processes needed to create individualized cell therapies, including chimeric antigen receptor (CAR) T therapies. The shuttle is a modular tool consisting of hardware, software, robotics, and consumables with the capability of producing 10 patient doses simultaneously. The single platform allows preclinical development efforts to easily transfer to the clinical environment.

Cellares estimates that the Cell Shuttle can lower costs by up to 75% and shorten time to market by as much as one to two years.

The series B financing was led by new investor Decheng Capital and co-led by existing investor Eclipse Ventures.

Cellares' scalable factory-in-a-box. Image courtesy of Cellares.

TCR2 to establish commercial cell therapy manufacturing in Md.
TCR2 Therapeutics has signed a long-term lease for an existing 85,000-sq-ft cell therapy manufacturing facility in Rockville, MD, which is ready for current...

Lyell completes $65M cell therapy manufacturing facility
Lyell Immunopharma has completed its $65 million Lyfe Manufacturing Center in Bothell, WA. The facility will be used to produce cell products for...

ONK strengthens cell therapy manufacturing capabilities
ONK Therapeutics has entered into a license agreement with the U.S. National Institutes of Health to gain rights to make and use clinically validated...

Takeda opens new cell therapy manufacturing facility
Takeda Pharmaceuticals said it has opened a new 24,000-sq-ft research and development (R&D) cell therapy manufacturing facility at its R&D headquarters...